Akilov, O., Huen, A., Pro, B., Modi, D., Mohrbacher, A., Haverkos, B. M., Scarmoutzos, L., Burns, M. C., Holsapple, E., Massey, K., Parchment, R. E., Donekal, Y., Moiin, A. (2025). A phase 1a/1b trial in relapsed/refractory T-cell non-Hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, an intravenous fenretinide phospholipid suspension (12.5 mg/mL).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7096